Document Type
Article
Publication Date
2026
DOI
10.4193/Rhin25.714
Publication Title
Rhinology
Volume
64
Issue
5
Pages
627-635
Abstract
Background: Evidence of dupilumab's real-world effectiveness in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in US clinical practice is limited.
Objective: To investigate healthcare resource utilization (HCRU) and medication use in patients with CRSwNP before and after dupilumab initiation in real-world US clinical practice.
Methods: This retrospective observational study included adults with CRSwNP who initiated dupilumab 300 mg every 2 weeks between June 2019 and June 2022. Data including claims and electronic health records were extracted from the OM1 Real-World Data Cloud and Reg-ENT Registry. Medication use, healthcare visits, sinus procedures, and imaging were assessed during the 12 months before (baseline) and after (follow-up) dupilumab initiation.
Results: The study comprised 1,016 patients (mean age 53.8 years, 46.1% female). Annual mean [standard deviation] number of visits per patient was lower during follow-up vs baseline for outpatient (5.0 [5.2] vs 7.1 [6.0]), otolaryngologist (3.7 [6.7] vs 4.0 [6.1]) and emergency department visits (0.1 [0.6] vs 0.2 [0.6]). The proportion of patients prescribed oral corticosteroids for any reason was lower during follow-up (28.7% vs 68.1%, respectively. Fewer patients were prescribed antibiotics (31.8% vs 64.6%) and CRSwNP related oral corticosteroids (17.7% vs 59.1%), and fewer patients underwent nasal endoscopy (47.5% vs 71.2%) and CT scan (4.5% vs 22.1%) during follow-up than at baseline.
Conclusions: These findings suggest an association between dupilumab treatment and reductions in HCRU and medication use in patients with CRSwNP, and provide supportive evidence of dupilumab's real-world effectiveness.
Rights
© 2026 The Authors.
Published under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.
Data Availability
Article states: "Qualified researchers may request access to the data and related study documents that support the findings of this study. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at https://www.vivli.org."
Original Publication Citation
Han, J. K., Lee, S. E., Peters, A. T., Soler, Z., Kamal, N., Nash, S., Corbett, M., Radwan, A., & Levy, J. (2026). Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP. Rhinology, 64(5), 627-635. https://doi.org/10.4193/Rhin25.714
Repository Citation
Han, J. K., Lee, S. E., Peters, A. T., Soler, Z., Kamal, N., Nash, S., Corbett, M., Radwan, A., & Levy, J. (2026). Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP. Rhinology, 64(5), 627-635. https://doi.org/10.4193/Rhin25.714
Included in
Applied Statistics Commons, Chemical Actions and Uses Commons, Diseases Commons, Other Rehabilitation and Therapy Commons, Pharmacy and Pharmaceutical Sciences Commons